Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This study is designed as a Phase II/III, multi-center trial, comparing two transplant
strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell
Transplantation (HSCT) will improve long-term progression-free survival compared to
autologous HSCT. Recipients will be biologically assigned to the appropriate treatment arm
depending on the availability of a Human Leukocyte Antigen (HLA) matched sibling.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) National Marrow Donor Program